Quality of life as a primary endpoint in ovarian cancer trials
Mené sur 822 patientes atteintes d'un cancer avancé de l'ovaire, cet essai franco-italien de phase III évalue l'efficacité, du point de vue de la survie sans progression et de la qualité de vie, et la toxicité d'une combinaison carboplatine-paclitaxel administrée une fois par semaine ou une fois toutes les trois semaines
Multimodal treatment of patients with advanced ovarian cancer consists of radical debulking surgery and a combination of platinum and taxane chemotherapy. Although this approach is highly effective and potentially curative, most women will relapse, which can be treated effectively but is rarely cured. In this context, quality of life is an important outcome measure. Unfortunately, few detailed analyses of quality of life have been done in large first-line treatment trials for ovarian cancer ...
The Lancet Oncology , commentaire, 2013